Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT – Research Report), ...

MariTide (maridebart cafraglutide; previously AMG 133) has emerged as one of Amgen's most promising pipeline projects thanks to its potential to offer once-monthly or even less frequent dosing ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Along with AT&T and T-Mobile, they provide the majority of mobile-phone services in the U.S. Verizon generated more than $133 billion in ... as of June 2024. Amgen is a biotechnology company ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

8.2 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 and s. 54(1) of the Patent Act, 1985. On Sept. 17, 2024, in Bayer Inc. v. Amgen Canada Inc., 2024 CanLII 117240 (FC), the ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...